Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Orbis Medicines logo — Reshaping the future of drug discovery

Orbis Medicines

Reshaping the future of drug discovery

Founded 2021 Denmark Denmark 47 employees Series A Total: $116.00M

General Information

Company Name Orbis Medicines
Founded Year 2021
Location Denmark Denmark
Employees 47
Funding Stage Series A
Business Model B2B, Platform, API
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Orbis Medicines. To contact Orbis Medicines, visit orbismedicines.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Orbis Medicines compare?

A PDF of Orbis Medicines and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Orbis Medicines soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Orbis Medicines

Orbis Medicines, founded in 2021, is at the forefront of transforming drug discovery. With the slogan "Reshaping the future of drug discovery," the company is dedicated to developing a comprehensive platform designed to discover, develop, and deliver drug candidates targeting challenging medical conditions.

Headquartered in Denmark, Orbis Medicines successfully closed a €26.00M Seed Round investment on 29 February 2024. This financial backing from notable investors, Novo Holdings and Forbion, underscores strong confidence in the company’s innovative approach and its potential to influence the pharmaceutical industry significantly.

The company's cutting-edge technology, supported by influential industry players, positions it as a compelling prospect for investors looking to engage in the rapidly advancing biopharmaceutical field. As Orbis Medicines continues its journey, it promises to be a significant contributor to future breakthroughs in drug discovery.

Business keywords: drug discovery, macrocyclic chemistry, computational platform, high-throughput screening, challenging targets, pharmaceutical innovation, platform development, drug candidates, medicinal chemistry, targeted therapy, biopharmaceuticals, chemoinformatics

Services & Products

Development of oral macrocycle drug candidates
Exploration and optimization of macrocycle chemical space
Integration of AI and large-scale data for drug discovery
Collaborative research and licensing agreements

Target Customers

Healthcare Providers Pharmaceutical Companies Biotechnology Researchers Patients requiring biologic drug alternatives

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series A €90.00M 6
Novo Holdings Forbion Cormorant Asset Management
Novo Holdings, Forbion +4
01 Jan 2025
Seed €26.00M 2
Novo Holdings
Novo Holdings, Forbion Capital Partners
01 Feb 2024
Round Undisclosed -
01 Sep 2021
Spinout Undisclosed 1
EPFL Swiss Federal Institute of Technology in Lausanne
01 Jan 2021

Orbis Medicines Alternatives & Competitors

View All Alternatives
Orbis Medicines vs
Septerna
Septerna United States

Bringing a new era of GPCR medicines to patients with its Native Complex Platform™.

IPO
137 employees
Biotechnology, Pharmaceutical
Compare Orbis Medicines vs Septerna
Orbis Medicines vs
Anagenex
Anagenex United States

Evolving new small molecule medicines by combining ultra high throughput biochemistry and machine le...

Series A
5 employees
Compare Orbis Medicines vs Anagenex
Orbis Medicines vs
CrystalsFirst
CrystalsFirst Germany

Turning Insights Into Medicines

Non Equity Assistance
18 employees
AI, Biotechnology
View all alternatives

FAQ About Orbis Medicines

Reshaping the future of drug discovery
Orbis Medicines was founded in 2021.
Orbis Medicines is headquartered in Denmark.
Orbis Medicines has a B2B, Platform and API business model. Its revenue comes from Licensing, Product Sales and Service Fee.
Orbis Medicines has approximately 47 employees.
Orbis Medicines has completed 4 funding rounds, raising a total of $116.00M. The latest funding stage is Series A.
Orbis Medicines offers: Development of oral macrocycle drug candidates, Exploration and optimization of macrocycle chemical space, Integration of AI and large-scale data for drug discovery, Collaborative research and licensing agreements.
Top alternatives and competitors to Orbis Medicines include Septerna, Anagenex, CrystalsFirst, Nexo Therapeutics, BellBrook Labs. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Orbis Medicines and Septerna are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Orbis Medicines, https://bouncewatch.com/company/orbis-medicines, updated 21 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout